finance.yahoo.com
Neutralfinance.yahoo.com ·
Why Repligen Rgen Shares Plunging
PharmaceuticalsMedicalHealth TechnologiesHealth Nutrition And Populati…
Topic context
This topic has been covered 387663 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedInsider sale by CEO of Repligen (bioprocessing equipment supplier) triggers negative sentiment and share price decline. No direct commercial mechanism on product/commodity prices or supply chains; impact is limited to equity valuation and investor confidence. Sector: life sciences tools.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- CEO Olivier Loeillot sold 3,832 shares for $536,480 under a Rule 10b5-1 plan established in August 2025.
- Repligen stock dropped 5.3% on the news.
- Stock is down 24.3% year-to-date, trading at $124.46, 27.7% below 52-week high of $172.26.
- Stock has had 15 movements exceeding 5% in the past year.
- Investors who bought $1,000 five years ago now have $575.29.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com
Canaan Can Q1 2026 Earnings Transcript
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com